Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Dec 2;19(1):232.
doi: 10.1186/s12890-019-1002-8.

Indwelling pleural catheters for malignancy-associated pleural effusion: report on a single centre's ten years of experience

Nikolaj Frost  1 , Martin Brünger  2 , Christoph Ruwwe-Glösenkamp  3 , Matthias Raspe  3 , Antje Tessmer  4 , Bettina Temmesfeld-Wollbrück  3 , Dirk Schürmann  3 , Norbert Suttorp  3 , Martin Witzenrath  3   5
Affiliations
Observational Study

Indwelling pleural catheters for malignancy-associated pleural effusion: report on a single centre's ten years of experience

Nikolaj Frost et al. BMC Pulm Med. .

Abstract

Introduction: Recurrent pleural effusion is a common cause of dyspnoea, cough and chest pain during the course of malignant diseases. Chemical pleurodesis had been the only definitive treatment option until two decades ago. Indwelling pleural catheters (IPC) emerged as an alternative, not only assuring immediate symptom relief but also potentially leading to pleurodesis in the absence of sclerosing agents.

Methods: In this single-centre retrospective observational study patient characteristics, procedural variables and outcome in a large population of patients with IPC in malignancy were evaluated and prognostic factors for pleurodesis were identified.

Results: From 2006 to 2016, 395 patients received 448 IPC, of whom 121 (30.6%) had ovarian, 91 (23.0%) lung and 45 (11.4%) breast cancer. The median length of IPC remaining in place was 1.2 months (IQR, 0.5-2.6), the median survival time after insertion 2.0 months (IQR, 0.6-6.4). An adequate symptom relief was achieved in 94.9% of all patients, with no need for subsequent interventions until last visit or death. In patients surviving ≥30 days after IPC insertion, pleurodesis was observed in 44.5% and was more common in patients < 60 years (HR, 1.72; 95% CI, 1.05-2.78; p = 0.03). The use of an additional talc slurry via the IPC was highly predictive for pleurodesis (HR 6.68; 95% CI, 1.44-31.08; p = 0.02). Complications occurred in 13.4% of all procedures (n = 60), 41.8% concerning infections (local infections at the tunnel/exit site (n = 14) and empyema (n = 11)), and 98.3% being low or mild grade (n = 59). Complication rates were higher in men than women (18.6 vs. 12.4%, p = 0.023).

Conclusion: High efficacy in symptom relief and a favourable safety profile confirm IPC as suitable first line option in most malignant pleural effusions. The study presents the largest dataset on IPC in gynaecologic cancer to date. Gender-specific differences in complication rates warrant further study.

Keywords: Indwelling pleural catheter; Malignant pleural effusion; Palliative care; Pleurodesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan-Meier curves for overall survival after date of primary diagnosis (OS1; a) and after IPC placement (OS2; b). Legend formula image
See this image and copyright information in PMC

References

    1. Rodriguez-Panadero F, Borderas Naranjo F, Lopez Mejias J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J. 1989;2(4):366–369. - PubMed
    1. Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. Eur Respir J. 2011;38(6):1425–1430. doi: 10.1183/09031936.00171610. - DOI - PubMed
    1. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20(4):654–659. doi: 10.1111/resp.12496. - DOI - PubMed
    1. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie ovarian Cancer study group) Ann Surg Oncol. 2010;17(6):1642–1648. doi: 10.1245/s10434-010-0964-9. - DOI - PubMed
    1. American Thoracic Society Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(5):1987–2001. doi: 10.1164/ajrccm.162.5.ats8-00. - DOI - PubMed

Publication types

LinkOut - more resources